Tibolone is a synthetic steroid with estrogenic, progestagenic and androgenic properties. The Million Women Study that included a large cohort of women screened for breast cancer analyzed the risk of ovarian cancer overall with use of tibolone which 22, did. Feb 17, · The synthetic hormone Livial, designed as an alternative to hormone replacement therapy, makes it significantly more likely a woman's breast cancer will .
RESULT(S): Mean breast density score decreased significantly from to in the tibolone group, compared with a significant increase in the CEE-MPA-treated group from to Ki67 expression decreased in 12 of 15, increased in 2 of 15, and remained unchanged in 1 of 15 subjects in the tibolone group, compared with 1 of 19, 15 of cardiovascular events with tibolone of [ , ] (2). • The data on breast safety have been contradictory. Preclinical data on tibolone concentrated on its effect on oestrogen metabolism in the breast. Tibolone and its metabolites reduce sulfatase and stimulate sulfotransferase activity thereby inhibiting the formation of active.
Tibolone, sold under the brand name Livial among others, is a medication which is used in menopausal hormone therapy and in the treatment of postmenopausal osteoporosis and endometriosis. The medication is available alone and is not formulated or used in combination with other medications. It is taken by mouth.. Side effects of tibolone include acne and increased hair growth among others. Dec 07, · Tibolone, which does not increase mammographic breast density, has proven to be effective and thus could be an important treatment option for women persistently seeking help. The objective of this trial is to demonstrate safety, efficacy and tolerability of oral mg tibolone daily in breast cancer patients, who, after surgery, have no.
Oct 01, · Tibolone is a relatively new drug for postmenopausal women, which is structurally related to nortestosterone derivatives and exhibits weak oestrogenic, progestogenic and androgenic activities. The effect of tibolone on breast tissue is still obscure. In vitro studies have shown conflicting results regarding the effects of tibolone on breast. CONCLUSION(S): The Tibolone Histology of the Endometrium and Breast Endpoints Study is a prospective, randomized clinical trial, designed to provide evidence of the endometrial safety of tibolone compared with estrogen and progestogen. Screening endometrial histology shows a low prevalence of endometrial hyperplasia (%) and no carcinoma. PMID.